Is crizotinib a medically insured drug?
Crizotinib is a drug used to treat ALK-positive or ROS1-positive non-small cell lung cancer. Crizotinib has been included in the national medical insurance directory at the end of 2020. This means that eligible medical insurance participants can obtain certain cost reimbursement according to local medical insurance policies when using crizotinib.
Reimbursement by medical insurance for crizotinib is usually limited to patients with ALK-positive or ROS1-positive locally advanced or metastatic non-small cell lung cancer. Before using crizotinib, patients must be diagnosed by a doctor and confirmed to be within the scope of medical insurance payment.
Specific reimbursement ratios, payment limits, usage conditions, etc. may vary depending on region and time. Therefore, during actual use, it is recommended that patients learn more about local medical insurance policies and consult professional medical or insurance institutions to obtain accurate information.
After crizotinib was included in medical insurance, its price was lower than before it was not included in medical insurance, reducing the financial burden for patients. However, patients still need to bear some out-of-pocket costs, which depend on local health insurance policies and reimbursement rates.
Medical insurance policies may change over time, so it is recommended that patients consult their local medical insurance department or medical institution for the latest reimbursement policies and cost status each time before purchasing or using crizotinib.
Even if crizotinib is included in medical insurance, patients may still have to bear part of other expenses incurred during treatment (such as examination fees, hospitalization fees, etc.). Therefore, when formulating treatment plans, patients should fully consider their own financial status and medical insurance policies.
Crizotinib is a prescription drug and needs to be used under the guidance of a doctor. Patients can purchase drugs through formal channels (such as hospital pharmacies or designated retail pharmacies) and follow the doctor's medication instructions for treatment.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)